Hans Bishop, Grail CEO (Victor J. Blue/Bloomberg via Getty Images)
September 16, 2020 11:21 AM EDTUpdated 11:56 AM
Deals
R&D

For­get the IPO, Il­lu­mi­na is near­ing a buy­out of $1.9B liq­uid biop­sy start­up Grail — re­port

Jason Mast

Editor

Grail, the $1.9 bil­lion, Jeff Be­zos-backed liq­uid biop­sy start­up, may not be go­ing pub­lic af­ter all.

Wednes­day morn­ing, a week af­ter the biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times